| |
|
|
|
|
|
 |
| |
|
Àϵ¿Çª·¹ÆÄ·¹¼ð¿¡Ä¡¿¬°í PREPARATION-H OINT.
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
642901900[A03403781]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2006.11.01)(ÇöÀç¾à°¡)
\92 ¿ø/1g(2000.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ŸÀÓÀ¯ÀÇ Çâ±â¸¦ °®´Â ¸Å²ô·¯¿î Ȳ»öÀÇ ¿¬°íÁ¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
20,28,56,112g
|
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 28±×·¥ |
1 °³ |
8806429019003 |
8806429019027 |
|
| 28±×·¥ |
1 °³ |
8806429019003 |
8806429019010 |
|
|
| ´ëÇ¥ÄÚµå |
8806429019003 |
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Ä¡ÇÙÀ¸·Î ÀÎÇÑ ´ÙÀ½ Áõ»óÀÇ ÀϽÃÀû ¿ÏÈ; ºÒÄè°¨, ÀÛ¿°¨, °¡·Á¿ò
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Phenylephrine]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:337700COM ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
- °¡´ÉÇϸé ȯºÎ¸¦ ÀûÀýÇÑ Æ¼½´·Î µÎµå·Á¼ ´Û¾Æ³»°í °ÇÁ¶½ÃŲÈÄ ÀÌ ¾àÀ» »ç¿ëÇÑ´Ù.
- ƯÈ÷ ¹ã, ¾ÆÄ§ ¶Ç´Â ¹èº¯ÈÄ ¸¶´Ù 1ÀÏ 4ȸ±îÁö ȯºÎ¿¡ Á÷Á¢ ¹Ù¸¥´Ù. Á÷Àå³»¿¡ Àû¿ëÇÒ °æ¿ì ÁÖÀԱ⸦ Æ©ºê¿¡ ³¢¿ì°í Á÷Àå³» »ðÀÔÇÑ´Ù. »ç¿ë ÈÄ¿¡´Â ÁÖÀԱ⠿ܺο¡ ¹¯¾îÀÖ´Â ¿¬°í¸¦ ±ú²ýÀÌ ´Û°í ĸÀ» ¾º¿ö º¸°üÇÑ´Ù.
[Á¦Çüº°º¹¾àÁöµµ]
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[º¸±â]
|
| ±Ý±â |
½ÉÁúȯ, °íÇ÷¾Ð, °©»ó¼± Áúȯ, ´ç´¢º´, Àü¸³¼±ºñ´ë·Î ÀÎÇÑ ¹è´¢°ï¶õ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
- ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¹× ¼öÀ¯ºÎ
- ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°íÀִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
ÀÌ ¾à »ç¿ë¿¡ ÀÇÇØ ¹ßÀû, ºÎÁ¾, Àڱذ¨ µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù
|
| ÀϹÝÀû ÁÖÀÇ |
- Á¤ÇØÁø ¿ë¹ý¡¤¿ë·®À» Àß ÁöŲ´Ù.
- 7ÀÏÁ¤µµ »ç¿ëÇÏ¿©µµ Áõ»óÀÇ °³¼±ÀÌ ³ªÅ¸³ªÁö ¾ÊÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù.
- ÃâÇ÷ÀÌ ÀÖ´Â °æ¿ì Áï½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù.
|
| »óÈ£ÀÛ¿ë |
Ç÷¾Ð°ÇÏÁ¦, Ç׿ì¿ï¾àÀ» º¹¿ëÁßÀÎ °æ¿ì »ç¿ëÀü ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù. |
| ÀӺο¡ ´ëÇÑ Åõ¿© |
[ÀӺαݱ⠼ººÐ Á¶È¸]
- µ¿¹°½ÇÇè¿¡¼ ÅÂÀÚµ¶¼º(°íÅõ¿©·®¿¡¼ Âø»ó¼ö ¹× »ýÁ¸¼öÀÇ ¾ïÁ¦°¡ º¸¿´À½)ÀÌ º¸°íµÇ¾î ÀÖ°í ÀӺο¡ ´ëÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °Í ¹Ù¶÷Á÷ÇÏ´Ù.
- ´Ù¸¥ ÇØ¿ÁøÅë¼Ò¿°Á¦¿¡¼ žƼøÈ¯Áö¼ÓÁõ(PEC)ÀÌ ÀϾ´Ù´Â º¸°í°¡ ÀÖ´Ù.
- ÀӽŸ»±âÀÇ ·§Æ®¿¡ Åõ¿©ÇÑ ½ÇÇè¿¡¼ ÅÂÀÚÀÇ µ¿¸Æ°ü¼öÃàÀÌ º¸°íµÇ¾î ÀÖ´Ù.
|
| ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© |
¸ðÀ¯·ÎÀÇ ÀÌÇàÀÌ º¸°íµÇ¾î ÀÖÀ¸¹Ç·Î ¼öÀ¯ºÎ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù. |
| ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© |
- ½Å»ý¾Æ, ¿µ¾Æ, 4¼¼ ÀÌÇÏÀÇ À¯¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù.
- °í·ÉÀÚ´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³ª±â ½¬¿ì¹Ç·Î, ¼Ò·®ºÎÅÍ Åõ¿©¸¦ °³½ÃÇÏ´Â µî ȯÀÚÀÇ »óŸ¦ °üÂûÇÏ¸é¼ ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í(ÀϹÝÀû ÁÖÀÇÇ× ÂüÁ¶)
|
| Àû¿ë»óÀÇ ÁÖÀÇ |
- ÀÌ ¾àÀº Ç×¹®ºÎÀ§¿¡¸¸ »ç¿ëÇÏ°í ¾È°ú¿ëÀ¸·Î´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù.
- ÀÌ ¾àÀ» ¼Õ°¡¶ôÀ̳ª ´Ù¸¥ ±â±¸¸¦ ÀÌ¿ëÇÏ¿© Á÷Àå³» »ðÀÔÇÏÁö ¾Ê´Â´Ù.
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
- ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù.
- Á÷»çÀϱ¤À» ÇÇÇÏ°í µÉ ¼ö ÀÖÀ¸¸é ½À±â°¡ Àû°í ¼´ÃÇÑ °÷¿¡ ¹ÐÀüÇÏ¿© º¸°üÇÑ´Ù.
- ¿À¿ëÀ» ¸·°í ǰÁúÀÇ º¸Á¸À» À§ÇÏ¿© ´Ù¸¥ ¿ë±â¿¡ ¹Ù²Ù¾î ³ÖÁö ¾Ê´Â´Ù.
- ȱâ±Ùó¿¡ µÎÁö ¾Ê´Â´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ´ëÇ¥ÄÚµå |
8806429019003 |
| BIT ¾àÈ¿ºÐ·ù |
Ç÷°ü°ÈÁ¦, Á¤¸Æ·ù Ä¡·áÁ¦, Ä¡Áú¾à(Capillary stabilizer, Phlebitis, Varicose veins, Hemorrhoidal)
|
| ATC ÄÚµå |
Other agents for treatment of hemorrhoids and anal fissures for topical use / C05AX
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
256 (Ä¡Áú¿ëÁ¦ )
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
642901900[A03403781]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2006.11.01)(Ãֽžడ)
\92 ¿ø/1g(2000.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
ŸÀÓÀ¯ÀÇ Çâ±â¸¦ °®´Â ¸Å²ô·¯¿î Ȳ»öÀÇ ¿¬°íÁ¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
20,28,56,112g
|
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â |
µ¿ÀÏÁÖ¼ººÐÄÚµå °Ë»ö¼øÀ§ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÷°¡Á¦ ÁÖÀÇ»çÇ× |
* ÷°¡Á¦ ÁÖÀÇ»çÇ×Á¤º¸´Â ÇöÀç ¾÷µ¥ÀÌÆ®ÁßÀÌ¸ç ¹Ì¾÷µ¥ÀÌÆ®µÈ ÀǾàǰÀÇ Ã·°¡Á¦
ÁÖÀÇ»çÇ×Àº Ç¥½ÃµÇÁö ¾ÊÀ»¼ö ÀÖ½À´Ï´Ù.
¡à ¾È½ÄÇâ»ê³ªÆ®·ý(º¯°æÁö½Ã Àǰü 65623-601È£, 2001.3.12)À» ´ÙÀ½°ú °°ÀÌ
º¯°æÇÑ´Ù.
¡à ¡°¾È½ÄÇâ»ê, ¾È½ÄÇâ»ê³ªÆ®·ý(¿Ü¿ëÁ¦ ¹× ÁÖ»çÁ¦¿¡ ÇÑÇÔ)¡± ÇÔÀ¯Á¦Á¦
¡Û »ç¿ë»óÀÇ ÁÖÀÇ»çÇ×
- ÀϹÝÀû ÁÖÀÇ
(¿Ü¿ëÁ¦) ÀÌ ¾àÀº ¾È½ÄÇâ»ê(³ªÆ®·ý)À» Æ÷ÇÔÇϰí ÀÖ¾î ÇǺÎ, ´«, Á¡¸·¿¡
°æ¹ÌÇÑ ÀÚ±ØÀÌ µÉ ¼ö ÀÖ´Ù.
(ÁÖ»çÁ¦) ÀÌ ¾àÀº ¾È½ÄÇâ»ê(³ªÆ®·ý)À» Æ÷ÇÔÇϰí ÀÖ¾î ½Å»ý¾Æ¿¡°Ô Ȳ´ÞÀÇ
À§ÇèÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù.
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(phenylephrine; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| Á¦Çüº° º¹¾àÁöµµ |
[¿¬°í] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Phenylephrine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Phenylephrine produces its ophthalmic and systemic actions by acting on alpha 1 adrenergic receptors in the pupillary dilator muscle and the vascular smooth musle, resulting in contraction of the dilator muscle and contraction of the smooth muscle in the arterioles of the conjunctiva and peripheral vasoconstriction. Phenylephrine decreases nasal congestion by acting on alpha 1 adrenergic receptors in the arterioles of the nasal mucosa to produce constriction.
|
| Pharmacology |
Phenylephrine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Phenylephrine is a powerful vasoconstrictor. It is used as a mydriatic, nasal decongestant, and cardiotonic agent. Phenylephrine is a postsynaptic alpha-receptor stimulant with little effect on the beta receptors of the heart. Parenteral administration of Phenylephrine causes a rise in systolic and diastolic pressures, cardiac output is slightly decreased and peripheral resistance is considerably increased, most vascular beds are constricted; renal, splanchnic, cutaneous, and limb blood flows are reduced but coronary blood flow is increased. Pulmonary vessels are constricted, and pulmonary arterial pressure is raised. This alpha receptor sympathetic agonist is also used locally because its vasoconstrictor and mydriatic action.
|
| Metabolism |
Phenylephrine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Monoamine oxidase type A (MAO-A)
|
| Protein Binding |
Phenylephrine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 95% binding-plasma proteins
|
| Half-life |
Phenylephrine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2.1 to 3.4 hours
|
| Absorption |
Phenylephrine¿¡ ´ëÇÑ Absorption Á¤º¸ Reduced bioavailability (compared to pseudoephedrine) following oral administration due to significant first-pass metabolism.
|
| Pharmacokinetics |
Phenylephrine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö½Ã°£
- ±ÙÀ°ÁÖ»ç, ÇÇÇÏÁÖ»ç : 10~15ºÐ À̳»
- Á¤¸ÆÁÖ»ç : Áï½Ã
- È¿°úÁö¼Ó½Ã°£
- ±ÙÀ°ÁÖ»ç : 30ºÐ ~ 2½Ã°£
- Á¤¸ÆÁÖ»ç : 15~30ºÐ
- ÇÇÇÏÁÖ»ç : 1½Ã°£
- ´ë»ç : Phenolic Æ÷ÇÕü·Î ´ë»çµÊ. Monoamine oxidase¿¡ ÀÇÇØ °£°ú Àå¿¡¼ ´ë»çµÊ.
- ¹Ý°¨±â : 2.5 ½Ã°£
- ¼Ò½Ç : ½Å¹è¼³ (90%)
PetrolatumsfertyyellowÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú ¹ßÇö : °æ±¸ : 6-8 ½Ã°£
- Èí¼ö : °ÅÀÇ Èí¼öµÇÁö ¾ÊÀ½
|
| Biotransformation |
Phenylephrine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Oral phenylephrine is extensively metabolised by monoamine oxidase, an enzyme which is present in the stomach and liver.
|
| Toxicity |
Phenylephrine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Phenylephrine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alseroxylon Increased arterial pressureIsocarboxazid Increased arterial pressureDeserpidine Increased arterial pressureGuanethidine The agent decreases the effect of guanethidineRasagiline Increased arterial pressureMethyldopa Increased arterial pressureMidodrine Increased arterial pressurePargyline Increased arterial pressurePhenelzine Increased arterial pressureReserpine Increased arterial pressureTranylcypromine Increased arterial pressureOxytocin Possible marked increase of arterial pressureMethylergonovine Possible marked increase of arterial pressureLinezolid Possible increase of arterial pressureErgonovine Possible marked increase of arterial pressureTrimipramine The tricyclic increases the sympathomimetic effectProtriptyline The tricyclic increases the sympathomimetic effectNortriptyline The tricyclic increases the sympathomimetic effectClomipramine The tricyclic increases the sympathomimetic effectAmitriptyline The tricyclic increases the sympathomimetic effectAmoxapine The tricyclic increases the sympathomimetic effectDesipramine The tricyclic increases the sympathomimetic effectDoxepin The tricyclic increases the sympathomimetic effectImipramine The tricyclic increases the sympathomimetic effectMoclobemide Moclobemide increases the sympathomimetic effect
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Phenylephrine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.
|
| Drug Target |
[Drug Target]
|
| Description |
Phenylephrine¿¡ ´ëÇÑ Description Á¤º¸ An alpha-adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. [PubChem]
|
| Dosage Form |
Phenylephrine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IntramuscularLiquid IntravenousLiquid OphthalmicOintment TopicalSolution IntravenousSolution / drops OphthalmicStrip OralTablet Oral
|
| Drug Category |
Phenylephrine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic alpha-AgonistsCardiotonic AgentsMydriaticsNasal DecongestantsSympathomimeticsVasoconstrictor Agents
|
| Smiles String Canonical |
Phenylephrine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CNCC(O)C1=CC(O)=CC=C1
|
| Smiles String Isomeric |
Phenylephrine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CNC[C@H](O)C1=CC(O)=CC=C1
|
| InChI Identifier |
Phenylephrine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
|
| Chemical IUPAC Name |
Phenylephrine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 3-[(1R)-1-hydroxy-2-methylaminoethyl]phenol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|